Health ❯Healthcare ❯Obesity

Treatment Options

GLP-1 Medications Weight Loss Injections GLP-1 Agonists Semaglutide Medication Efficacy Medication Mounjaro Pharmaceuticals Novo Nordisk Tirzepatide

Amgen Advances Monthly Obesity Drug to Phase 3 After 20% Weight Loss in Mid-Stage Trial

Amgen plans to use lower starting doses with gradual escalation to improve tolerability ahead of expanded Phase 3 studies

NHS Empowers GPs to Prescribe Mounjaro for Severe Obesity

Novo Nordisk’s Amycretin Delivers Up to 24% Early Weight Loss in Dual-Form Trials

France to Let All Doctors Prescribe Wegovy and Mounjaro Starting June 23

NHS Expands Mounjaro Rollout as Regulators Flag Safety Concerns

Bariatric Surgery Surpasses GLP-1 Drugs in Real-World Weight Loss

Mounjaro Delivers Rapid Weight Loss as UK Health Officials Warn of Serious Risks

Weight Management Revolution: GLP-1 Drugs Dominate as Pills Emerge

UK to Trial Pharmacy-Based NHS Weight-Loss Jab Prescriptions

Eli Lilly's Mounjaro Launches in India, Targeting Obesity and Diabetes

Poll Shows Americans Divided Over Weight-Loss Drugs for Obesity Treatment

Novo Nordisk's Amycretin Shows 22% Weight Loss in Trial, Boosting Stock

Medicare to Cover Eli Lilly’s Zepbound for Sleep Apnea Treatment

Experts Explore Potential of Ozempic Microdosing for Health Beyond Weight Loss

Limited Access to Popular Weight-Loss Drugs Highlights Socioeconomic Disparities

Ozempic Shows Promising Mental Health and Cognitive Benefits

New Research Highlights Key Factors for Effective Weight Loss with GLP-1 Drugs

Novo Nordisk's Amycretin Pill Shows Promising Weight Loss Results in Early Trial

UK Approves Wegovy for Reducing Heart Risks in Overweight Patients